Factual Summary
Iovance Biotherapeutics reported Q2 results on 2026-08-06, posting revenue of USD 99.3 million (above the market consensus of USD 87.8 million, up 66% year-over-year). Amtagvi revenue was approximately USD 91 million, exceeding the high end of the company's own guidance, and gross margin reached a record 56%. On the same day, the company disclosed that the FDA had granted Fast Track Designation to lifileucel for soft tissue sarcoma. The company stated it is reviewing its existing FY2026 annual revenue guidance (USD 350-370 million) and plans to update it at the Q3 earnings release.
Price-Change Context Note
The reference-date (2026-08-06) closing price was USD 6.21, up +43.09% from the previous close (USD 4.34), with volume of 73,430,649 shares — about 3.8x the 20-day average volume (19,315,752 shares). The rally reflects the Q2 revenue surprise, gross margin improvement, and narrower loss announced the same day; the prior trading day (2026-07-31) had fallen -14.07%.
Business Overview — TIL Cell Therapy Amtagvi
Amtagvi (lifileucel) is the first one-time-infusion TIL (tumor-infiltrating lymphocyte) cell therapy to receive FDA accelerated approval, for adult patients with unresectable or metastatic melanoma who progressed after anti-PD-1 therapy. Following conditional approval from Australia's TGA in June 2026, the therapy now has formal marketing authorization in a cumulative three countries, and is available for prescription at more than 95 authorized treatment centers in the US (BioSpace, 2026-08-06). Registrational trials and early-stage data are ongoing in sarcoma (the SARATOGA trial) and uterine serous carcinoma, among others, and on 2026-08-06 the FDA granted lifileucel Fast Track Designation for soft tissue sarcoma. The European (EMA) marketing application, withdrawn in July 2025, is being prepared for resubmission, and no European revenue has yet been generated.
5-Year Revenue and Profit/Loss Trend
| Fiscal Year | Total Revenue | Net Loss | Notes |
|---|---|---|---|
| FY2023 | USD 1.2M | USD -444.0M | Small revenue began following Proleukin acquisition |
| FY2024 | USD 164.1M | USD -372.2M | First year of commercialization after Amtagvi accelerated approval |
| FY2025 | USD 263.5M | USD -391.0M | Total expenses USD 666.9M, EPS -1.09 |
In FY2026, quarterly revenue expanded from approximately USD 71 million in Q1 (GlobeNewswire, 2026-05-07) to USD 99.3 million in Q2, while gross margin improved from 41% to 56%. Detailed FY2021/FY2022 research and development and SG&A expense line items, exact FY2023/FY2024 EPS figures, and cash-flow-statement details such as free cash flow were not obtained in this research.
Competitive Landscape
Iovance is the only company with an FDA-approved TIL cell therapy for solid tumors, and industry commentary suggests comparable cell-therapy competitors are not expected to enter the market until around 2027 (as cited by Seeking Alpha). Replimune's Tudriqev (RP1), a close competing pipeline candidate, received a CRL (Complete Response Letter) from the FDA. The most recent Amtagvi response-rate data (updated 2026-02) reported a 44% response rate among melanoma patients.
Whether major pharmaceutical companies such as Bristol Myers Squibb and Merck have directly competing TIL programs, quantitative comparisons with companies such as Obsidian Therapeutics and Turnstone Biologics, and market share relative to competitors were not obtained in this research.
Valuation (Factual Multiples)
Supply & Demand — Short Interest and Institutional Holdings
As of the 2026-07-15 settlement date, short interest was 99,892,938 shares, or 25.75% of the float (22.37% of shares outstanding), with Days to Cover of 5.91. This data predates the heavy trading (+43.09%, 73,430,649 shares) triggered by the 2026-08-06 earnings release; since the next settlement date (for 2026-07-31) is scheduled to be reported around 2026-08-08, whether short covering occurred on the day of the surge was not confirmed in this research.
Total institutional holdings, per Q1 2026 (as of 2026-03-31) 13F filings, were 269,131,002 shares (approximately 60.28% of shares outstanding, recalculated by businessquant.com). The Q2 2026 (as of 6/30) 13F filing deadline is 2026-08-14, so institutional trading activity reflecting the post-surge period was not yet available at the time of this research. Dark pool trading share, daily short-volume ratio, and retail trading trends were also not obtained in this research.
Governance and Capital Structure
Per the DEF 14A filed 2026-04-28 (Record Date 2026-04-15), the combined ownership of the four shareholders holding more than 5% was 24.2%. The board consists of 7 members (Chair Iain Dukes), and the largest shareholder, Wayne Rothbaum, serves as a director. The former CEO resigned following an FDA complete response in May 2021, and Frederick Vogt, then General Counsel, was appointed Interim CEO on 2021-06-10, retaining the interim title for more than five years. Following CFO Jean-Marc Bellemin's departure on 2025-06-30, an interim arrangement was in place until Corleen Roche was formally appointed CFO on 2025-08-06.
| Date | Capital Structure / Governance Event |
|---|---|
| 2024-02 | Issued 23,014,000 new common shares via public offering |
| 2025-06-30 | CFO Jean-Marc Bellemin departs; transition to interim arrangement |
| 2025-08-06 | New CFO Corleen Roche takes office |
| 2025-08-22 | Entered into ATM program agreement with Jefferies for up to USD 350 million |
| 2026-06-10 | Annual meeting — proposals including increase in authorized common shares from 500 million to 650 million |
| 2026-06-18 | Filed S-3ASR shelf registration and registered an additional USD 89.65 million under the ATM program |
A full review of Form 4 filings from 2025-01-01 to 2026-08-07 found no discretionary open-market dispositions (Code S). Three open-market acquisitions (Code P) were identified, in which officers Vogt, Puri, and Kirby each purchased small amounts of stock with personal funds in the open market when the share price was in the USD 1.7-1.8 range during May-June 2025. There have been no ownership-change filings from the largest shareholder, Wayne Rothbaum/Quogue Capital, since 2024-03-19. Exact ownership percentages by subsidiary, sub-subsidiary relationships, and the actual voting results of the 2026-06-10 annual meeting were not obtained.
Macro Environment
| Factor | Reference-Date Value | Notes |
|---|---|---|
| Federal Funds Rate | 3.50-3.75% (held at 2026-07-29 FOMC meeting) | Three dissents favoring a hike |
| US 10-Year Treasury Yield | 4.61% (2026-08-06) | Slightly below the year's high of 4.75% |
| XBI (Biotech ETF) | 154.50 (2026-08-06, +0.97%) | Trending to new highs after closing 2025 up +35% |
| KRW/USD Exchange Rate | KRW 1,422.15 (2026-08-05) | IOVA's revenue and expenses are entirely USD-denominated, limiting direct transmission |
| Biotech M&A Volume (H1 2026) | USD 134 billion | Above the USD 112 billion in the same period last year, with active acquisitions of cell-therapy platforms |
The company manufactures Amtagvi entirely in the US at its own Philadelphia facility (iCTC), so it is not directly subject to the pharmaceutical import tariff executive order signed in April 2026. The trend toward FDA regulatory easing for cell and gene therapy manufacturing rules is favorable for capacity expansion, but the continuation of acting-director leadership at the CDER and CBER review divisions is cited as a source of uncertainty for the timeline of indication-expansion reviews.
News Timeline
| Date | Description |
|---|---|
| 2026-07-17 | Disclosed a grant of 139,930 inducement stock options under Nasdaq Listing Rule 5635(c)(4) (exercise price USD 4.66) |
| 2026-07-30 | Officially announced Q2 earnings release schedule (8/6, 8:30 AM ET) |
| 2026-07-31 | Share price fell -14.07% (to around USD 4.03); no specific single triggering news identified |
| 2026-08-06 | Q2 earnings released (revenue USD 99.3M, above consensus) and soft tissue sarcoma Fast Track Designation disclosed; share price surged +43.09% |
Specific post-earnings estimate revisions by individual brokerages (with date and institution named) were not obtained. Reports of acquisition interest from major pharmaceutical companies were treated as low-confidence, speculative secondary coverage, as no specific acquirer or formal process was confirmed.
Risk Factors
A USD 350 million ATM program is active, and shares outstanding increased +8.4% over the two months from 2026-02-13 to 04-15.
Due to the cost burden of cell-therapy manufacturing, gross margin remained at 41-50% through 2025 and improved to 56% in Q2 2026, though whether this is sustainable has not been confirmed.
The company has stated it has funding sufficient into the second half of 2028, but some media outlets present conflicting assessments, so this is not a single confirmed figure.
Amtagvi was approved via the accelerated approval pathway, so whether conditional approval is maintained is structurally dependent on confirmatory trial results.
As seen in the +43.09% single-day surge on 2026-08-06, event-driven share price volatility is high, and trading volume also spiked (73,430,649 shares).
Specific confirmatory-trial timelines, the existence of litigation or patent disputes, and details of manufacturing-facility supply chain risk were not obtained in this research.
Theme Relevance
Fact Highlights
This is not investment advice. FomoLog provides factual summaries and post-hoc price-change context only. Investment decisions and their outcomes are solely the responsibility of the investor.
Generated by FomoLog Agent · Data sources: Korea Exchange · NASDAQ · DART · SEC EDGAR